Location United States, North America Gender Male
LinkedIn View on LinkedIn
Dr. Michael Jensen graduated from the University of Pennsylvania School of Medicine then completed training in Pediatric Hematology and Oncology at the University of Washington/Fred Hutchinson Cancer Research Center. Dr. Jensen trained in the laboratory of Philip Greenberg and received AACR’s 1996 Fellowship in Clinical/Translational
Research.
Following completion of his fellowship, Dr. Jensen joined the faculty at the Beckman Research Institute at City of Hope where he served for thirteen years and progressed from an Assistant Professor to a full Professor. There, Dr. Jensen built a translational research program integrating synthetic antigen receptor design and T cell gene transfer as a strategy to implement immunotherapy for cancer.
Dr. Jensen initiated the first CAR T cell trials using CD20 and CD19 specific CARs, as well as first in human trials for children with neuroblastoma and malignant gliomas. Based on this productivity, the Beckman Research Institute created the Department of Cancer Immunotherapeutics & Tumor Immunology and incorporated into the institution’s NCI-Comprehensive Cancer Center the Cancer Immunotherapeutics Program with Dr Jensen as its leader.
During his tenure at City of Hope, Dr Jensen’s research program placed a strong emphasis on bench-to-bedside translational research and resulted in five FDA-authorized Investigational New Drug Applications covering first-in-human applications of adoptive transfer of genetically engineered T-cells having re-directed tumor specificity for lymphoma, neuroblastoma, and malignant gliomas.
Dr. Jensen joined the University of Washington School of Medicine faculty in 2010 as the Sinegal Endowed Professor of Pediatrics. He is a Joint Member of the FHCRC’s Division of Clinical Research and is an Adjunct Professor of Bioengineering at the UWSOM. His laboratory research program is located at the Seattle Children’s Research Institute, and he is the founding director of the Ben Towne Center for Childhood Cancer Research. He has founded SCRI’s new Program in Cell and Gene Therapy and directs the institute’s Therapeutic Cell Production Core.
